In the pharmaceutical industry, we have witnessed a dramatic expansion of the use of real-world data throughout the product’s lifecycle. Currently, real-world evidence (RWE) is an essential element of safety and effectiveness assessments, market access processes, and clinical development of innovative products, to name a few.
And when generating RWE, there’s no data like Nordic data.
In the latest episode of Expert Opinions, MedEngine’s Scientific Consultant Mirkka Koivusalo shares her views on why the Nordics provide unique opportunities for RWE research.
At MedEngine, we specialize in Nordic RWE projects. We have a deep understanding of data sources, study permit practices, and regulations in each country. We also have local team members in Denmark, Finland, and Sweden, who are responsible for handling the local study permit procedures to ensure effective management of study procedures.
Are you interested in learning more about the Nordic RWE landscape? Please send an email to firstname.lastname@example.org or contact directly our CEO Tero Ylisaukko-oja below. We’d be happy to share our insights and experiences!